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a  b  s  t  r  a  c  t
Objective: The objective of this study was to verify the evolution of pregnancies in sickle cell
patients followed at one institution over a period of 12 years (January 2000 to June 2012).
Methods: The study evaluated 34 pregnant women with sickle cell disease with a mean age
of  23.9 ± 5.3 years. The incidence of obstetric complications, non-obstetric complications
linked to sickle cell disease and complications in the newborn were analyzed.
Results: A total of 26% of the cases reported previous miscarriages, 20% had preterm
labor, 10% had pre-eclampsia, and 5% had gestational diabetes. Forty-one percent of the
deliveries were cesarean sections and 29% of patients required blood transfusions. In
respect to sickle cell disease, 62% of patients had vaso-occlusive crises, 29% had acute chest
syndrome, 23% had urinary tract infection, 15% had impaired cardiac function and 6%
developed pulmonary hypertension. Only one patient died in the postnatal period due to
acute  chest syndrome. The mean gestational age was 37.8 ± 2.63 weeks, and mean newborn
weight was 2.809 ± 643.8 g. There were seven fetal losses, including three stillbirths and four
miscarriages. The impact of transfusion therapy on the incidence of maternal–fetal
complications during pregnancy was evaluated.
Conclusions: Pregnancy in sickle cell patients is still associated with complications. Although
no  statistical difference was observed between transfused and non-transfused women,
there were no deaths (fetal or maternal) in transfused patients whereas one maternal death
and  three stillbirths occurred in non-transfused women. A larger study of sickle cell pregnant
women will be necessary to elucidate the actual role of transfusion during pregnancy in
sickle cell disease.
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Table 1 – Characteristics of the patients according to
their sickle cell genotype.
Hb SS Hb S/beta0 Hb SC
Number of patients 24 7 3
Mean age (years) 22.6 22.0 25.0
Previous HU use – n (%) 5 (21) 2 (28) 1 (33)
Blood transfusion – n (%) 5 (21) 4 (57) 1 (33)330  rev bras hematol hem
Introduction
Sickle cell disease (SCD) comprises a group of diseases char-
acterized by the presence of sickle hemoglobin (Hb S). It is
classiﬁed as sickle cell anemia (Hb SS), hemoglobinopathy
SC, hemoglobinopathy SD, S-beta thalassemia (Hb S-beta) and
other associations of mutant hemoglobins with Hb S.
In situations of low oxygen tension, Hb S solubility
decreases, resulting in the polymerization of these molecules.
The intracellular formation of Hb S polymers affects the
red cell structure, changing it into a sickle-shaped, thereby
damaging the cell membrane, making it more  rigid and
exposing a greater number of adhesion molecules on the
cell surface, thus increasing the adherence of red cells to
the vascular endothelium.1 This phenomenon, named sick-
ling, is responsible for the premature destruction of red
cells by the reticuloendothelial system, causing a chronic
hemolytic anemia. Under stress situations, such as infec-
tions, deoxygenation of Hb molecules and sickling of a
large number of red blood cells occur. These cells adhere
to the vascular endothelium which may cause vessel occlu-
sion and, consequently, tissue ischemia causes the painful
crises that characterize one of the clinical features of
this disease. Chronic hemolytic anemia and frequent vaso-
occlusive crises cause damage to various organs and impair
both the survival and the quality of life of patients with
SCD.2
Until the 1970s, the management of sickle cell patients
was poor and pregnancy was associated with high mater-
nal and fetal mortality.3 Nowadays, with newborn screening
and preventive measures such as vaccination and antibiotic
prophylaxis since birth, patient survival has improved.4 Fur-
thermore, the quality of obstetric and neonatal care has also
corroborated to a signiﬁcant reduction in the maternal mortal-
ity rate (from 4.1% to 1.7%) and improved fetal survival (from
60 to 80%).4,5 However, despite all the medical advances in
recent decades, pregnancy in sickle cell patients is still associ-
ated with many  clinical and obstetric complications compared
to the general population.6–8
The physiological adaptations that occur in the circulatory,
hematologic, renal, and pulmonary systems during pregnancy
can overburden organs that already have chronic injuries sec-
ondary to SCD, increasing the rate of obstetric complications
such as eclampsia and pre-eclampsia as well as the compli-
cations of the disease, such as worsening of vaso-occlusive
crises and acute chest syndrome.7
Objective
The aim of this study was to assess the evolution of preg-
nancy in sickle cell patients followed at one institution, the
Faculdade de Medicina de Ribeirão Preto, Universidade de São
Paulo (HC-FMRP-USP) in a 12-year period (January 2000 to
June 2012), and discuss the impact of blood transfusion on
pregnancy.This study will contribute to the knowledge on the preva-
lence of maternal and fetal complications occurring in this
population and show the impact of therapeutic measures used
to control these complications during pregnancy.Obstetric complications – n (%) 14 (58) 1 (14) 1 (33)
Sickle cell complications – n (%) 18 (75) 6 (85) 2 (67)
Methods
This was a retrospective study that aimed at analyzing the evo-
lution of pregnancies in sickle cell patients during the period
covered by the study (January 2000 to June 2012).
Study  participants
The subjects comprised sickle cell patients followed at the
Hospital das Clinicas, Universidade de São Paulo (USP) in
Ribeirão Preto. Patient inclusion criteria were having a diag-
nosis of SCD (Hb SS, Hb S-beta or Hb SC) by hemoglobin
electrophoresis and having had one or more  pregnancies from
January 2000 to June 2012. The patients were then divided in
two groups in order to evaluate the impact of blood transfu-
sions on sickle cell complications during pregnancy.
Design
Clinical data was obtained through a review of medical records
from the hospital with the conﬁdentiality of information
being preserved. The results of laboratory tests were obtained
through the online hospital system using the ATHOS program.
The clinical and laboratory data were recorded on a data col-
lection form and later compiled for statistical analysis of the
prevalence of maternal and fetal complications.
Statistical  analysis
Data are presented as descriptive statistics including means
and percentages. The Mann–Whitney non-parametric sta-
tistical test was used to compare the transfused and
non-transfused groups as the samples did not have a Gaussian
(normal) distribution.
Results
The study evaluated 34 pregnant women with SCD; 24 (70.5%)
had Hb SS, seven (20.5%) Hb Sb0-thalassemia and three (8.8%)
Hb SC. The mean age was 23.9 ± 5.3 years and 20 (59%) were
followed from the ﬁrst trimester of pregnancy in the High-
risk Pregnancy Outpatient Service of the hospital, nine (25%)
started this follow-up in the last trimester, and ﬁve (15%) did
not have any follow-up in this service. The characteristics of
the patients according to the type of SCD are shown in Table 1.
Hb SS patients had more  obstetric complications (three
stillbirths, three miscarriages and eight pre-term labors and
one maternal death) than the other two genotypes (S/beta0
with one miscarriage and Hb SC with one pre-term labor). Most
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Table 2 – Maternal obstetric complications during
pregnancy.
Obstetric complications n (%)
Previous miscarriage 9 (26.6)
Preterm labor 8 (23.5)
Pre-eclampsia 4 (12.0)
Gestational diabetes 2 (5.8)
Cesarean section 14 (41.0)
Transfusion in peripartum period 10 (29.4)
Table 3 – Non-obstetric maternal complications during
pregnancy.
Non-obstetric complications n (%)
Vaso-occlusive crises 21 (61.7)
Acute chest syndrome 10 (29.4)


















Table 4 – Analysis of the characteristics of the newborn
infants.
Characteristic
Mean gestational age (weeks) – mean ± SD 37.8 ± 2.63
Average weight (g) – mean ± SD 2809 ± 643.8
First minute Apgar <7 – n (%) 11 (27.5%)
Stillbirth – n (%) 3 (7.7%)
Miscarriage – n (%) 4  (10.2%)
pregnancy due to the increased oxygen consumption andImpaired cardiac function 5 (14.7)
Maternal death 1 (2.9)
f the patients in all three groups experienced complications
elated to SCD during pregnancy.
bstetric  complications
he patients had many  obstetric complications, such as
revious miscarriage, preterm labor, pre-eclampsia, and ges-
ational diabetes (Table 2). Some patients required blood
ransfusions in the peripartum period for clinical complica-
ions such as acute chest syndrome, recurrent vaso-occlusive
rises and one had hyper-hemolytic syndrome.
on-obstetric  complications
he incidence of sickle cell complications during pregnancy is
hown in Table 3. Only one patient died two days after delivery
ue to acute chest syndrome.
haracteristics  and  complications  of  the  newbornhe main characteristics of the newborns are shown in Table 4.
here were seven fetal losses, including three stillbirths and
our miscarriages.
Table 5 – Comparison of maternal–fetal characteristics between
non-transfused during pregnancy.
Non-transfused (n
Median age (years) – mean (range) 23 (19–37) 
Pre-gestational Hb (g/dL) – mean (range) 8.45 (6.6–10.0)
Mean gest. age (weeks) 39.6 
Mean 1st minute Apgar score 7.3 
Mean weight at birth (g) 2850 (1415–30
Mean weight of placenta (g) 512.5 
C. section/normal delivery 6/15 
Miscarriage – n (%) 3 (12.5) 
Stillbirth – n (%) 3 (12.5) 
Maternal death – n (%) 1 (2.9) 
Total deaths (maternal and fetal) 4/48 
a One patient had two pregnancies.SD: standard deviation.
The impact of transfusion therapy during pregnancy was
also evaluated. The evolution of pregnancy, type of deliv-
ery, fetal characteristics and maternal complications were
compared between transfused and non-transfused pregnant
women. Approximately one third (10/34) of the patients were
submitted to transfusion during pregnancy and the results of
this analysis are presented in Table 5.
The indications for transfusion during pregnancy were:
acute chest syndrome (six patients), and repeated vaso-
occlusive crises (three patients); one patient was already on
a transfusion program due to cerebral vasculopathy.
Discussion
This study shows that despite the medical advances in recent
decades, pregnancy is still associated with many  clinical and
obstetric complications in patients with SCD, resulting in a
higher maternal and infant mortality than in patients with
the sickle cell trait (Table 6). All deaths (maternal and fetal)
occurred in Hb SS patients, the most severe genotype of SCD.
It is known that pregnancy induces a number of physiologic
changes that affect the hematologic indices, and patients with
SCD may experience worsening of the anemia and other sickle
cell complications.9
Oxygen demand during pregnancy increases to support
the metabolic requirements of the placenta and fetus. As
the maternal oxygen reserve may be compromised duringdecreased functional residual capacity, patients may be pre-
disposed to hypoxemia, with exacerbation of sickling and its
complications.10 These changes during pregnancy highlight
 pregnant women with sickle cell disease transfused and
 = 24) Transfused (n = 10) p-value
22 (18–32) 0.79
 8.2 (7.6–11.6) 1
37.5 0.87
7.8 0.79
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Table 6 – Comparison of maternal–fetal characteristics between two published studies and the current study.
Koshy et al.11 Nomura et al.8 Current study
Hb SS Hb SS + Hb SC Sickle cell trait Hb SS + Hb S/beta + Hb SC
Number of patients 100 51 56 34
Gestational age (weeks) 37.5 35.2 37.9  37.8
Weight <2500 g (%) 41.7 62.7 17.9 25.0
Previous miscarriage (%) 36.0 25.5 25.0 26.6
Perinatal death (%) 7.6 11.8 1.8 7.7
Cesarean section (%) – 84.3 73.2 41.1
Pre-eclampsia (%) 18.0 21.6 14.3 12.0
2
3
rGestational diabetes (%) – 
Maternal death (%) 1.7 
the need for a multidisciplinary team of experts to monitor
pregnant sickle cell women in a tertiary hospital.
When our results are compared to a Brazilian study pub-
lished in 2010 by Nomura et al. (Table 6), the maternal death
rate was similar despite differences in the obstetric compli-
cation rate (pre-eclampsia, gestational diabetes and cesarean
section).8 The largest difference occurred in the analysis of
fetal characteristics such as gestational age at delivery, weight
lower than 2500 g at birth and perinatal death. The gestational
age and perinatal death rate in this study were similar to the
publication by Koshy et al.11
In another recently published retrospective study, the
authors analyzed 68 SCD patients. Almost all of the patients
had at least one sickle cell complication during pregnancy, but
a lower rate of obstetric complications (15/68) compared to the
current study.12 In relation to newborn outcomes, a study per-
formed at a university hospital in the West Indies analyzed
perinatal outcomes such as admission to a nursery ward, birth
weight less than 2.5 kg, 5-min Apgar score less than 7, cesarean
section for fetal distress, and perinatal death or death before
discharge from nursery ward of 19 newborn babies. A total of
47% of the subjects had adverse outcomes.13
The need for transfusion during pregnancy for either acute
anemia or obstetric emergencies is common in SCD patients.
On the other hand, the use of prophylactic transfusions is still
polemic.14 According to Koshy et al., there is no need for pro-
phylactic transfusions during a non-complicated pregnancy.15
The authors performed a randomized controlled trial evaluat-
ing the beneﬁts of prophylactic transfusions during pregnancy
and found that maternal and fetal outcomes were simi-
lar in the transfused and non-transfused group. Subsequent
retrospective cohort studies evaluating the efﬁcacy of prophy-
lactic transfusions also failed to show a substantial decrease
in obstetric and fetal complications.16,17 Conversely, prophy-
lactic erythrocytapheresis in the third trimester has been
associated with a reduction in adverse maternal and fetus
outcomes.18
Although no statistical difference was observed between
transfused and non-transfused patients, there were no deaths
(fetal or maternal) in transfused women, whereas in non-
transfused patients, there was one maternal death and three
stillbirths. This observation leads us to question again the
role of transfusions in sickle cell patients during pregnancy, a
period prone to an increase in the percentage of maternal and
fetal complications. Perhaps the current study did not detect
any statistical signiﬁcance between the two groups due to the
1.0 12.5 6.0
.9 0 2.9
limited number of pregnant women analyzed. A randomized
multicenter study should be performed urgently to evaluate a
larger number of pregnant sickle cell women in order to better
elucidate this issue.
Conclusions
This study shows that pregnancy is still associated with many
clinical and obstetric complications in patients with SCD and
so patients should be followed by a multidisciplinary team in
a tertiary hospital.
The actual role of transfusion during pregnancy in SCD
remains to be determined however it seems that it should be
adopted more  liberally.
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